Curanex Pharmaceuticals Inc’s Lock-Up Period Set To Expire on February 23rd (NASDAQ:CURX)

Curanex Pharmaceuticals’ (NASDAQ:CURX) lock-up period is set to end on Monday, February 23rd. Curanex Pharmaceuticals had issued 3,750,000 shares in its initial public offering on August 26th. The total size of the offering was $15,000,000 based on an initial share price of $4.00. After the expiration of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Ratings Changes

Several brokerages have weighed in on CURX. Wall Street Zen downgraded shares of Curanex Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e-)” rating on shares of Curanex Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Curanex Pharmaceuticals Stock Performance

Shares of CURX opened at $0.32 on Friday. Curanex Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $9.18. The firm has a market capitalization of $9.06 million and a price-to-earnings ratio of -6.40. The firm has a 50 day simple moving average of $0.35.

Institutional Trading of Curanex Pharmaceuticals

An institutional investor recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new position in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.